Woodcock Warns of ‘Excessive Worship Of The RCT,’ Pushes New Drug Approval Pathway

 
• By Sarah Karlin-Smith
  
close up of person praying
Janet Woodcock said excessive focus on randomized controlled trials prevents openness to other avenues for regulatory approval. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from R&D